Q1 EPS Estimate for Evaxion Biotech A/S Boosted by Analyst

Evaxion Biotech A/S (NASDAQ:EVAX) – Equities research analysts at Zacks Small Cap upped their Q1 2025 earnings per share (EPS) estimates for Evaxion Biotech A/S in a research note issued on Wednesday, February 5th. Zacks Small Cap analyst B. Sorensen now expects that the company will earn ($0.75) per share for the quarter, up from their previous estimate of ($1.35). The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.43) per share. Zacks Small Cap also issued estimates for Evaxion Biotech A/S’s Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($1.49) EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.23 EPS and FY2026 earnings at $0.69 EPS.

Several other research analysts also recently commented on EVAX. Lake Street Capital reduced their price objective on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a report on Monday, February 3rd.

Evaxion Biotech A/S Trading Down 6.2 %

Shares of NASDAQ EVAX opened at $2.58 on Friday. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The business’s 50 day moving average price is $4.47 and its 200-day moving average price is $10.40. Evaxion Biotech A/S has a fifty-two week low of $2.22 and a fifty-two week high of $23.70. The company has a market cap of $3.02 million, a price-to-earnings ratio of -1.78 and a beta of -0.28.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new position in Evaxion Biotech A/S (NASDAQ:EVAX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S at the end of the most recent quarter. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.